fluvoxamine
This inexpensive, FDA-approved drug can significantly reduce the hospitalization and death rate from COVID-19
In a double-blinded randomized controlled clinical trial (n=152), Fluvoxamine completely prevented hospitalization and death from COVID-19 for those who took the drug (N=80) vs. placebo (N=72 with 6 meeting the hospitalization endpoint 8.3% ) p=.009. A study done a few weeks after that study was published